NGD 912

Drug Profile

NGD 912

Latest Information Update: 26 Jan 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neurogen Corporation
  • Developer Neurogen Corporation; Pfizer
  • Class Anxiolytics
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 26 Jan 2001 Discontinued-II for Anxiety disorders in USA (Unknown route)
  • 23 Jun 2000 Pfizer has merged with Warner-Lambert
  • 27 Mar 2000 Phase-II clinical trials for Anxiety disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top